Biodesix, Inc. (BDSX)

Over the past six months, Biodesix, Inc. has experienced several stock events related to its financial performance and operational updates. These events include Q3 2025 Earnings, Q4 2025 Earnings, Lung Nodule Biomarker Clinical Validation Study, AACR 2026 Posters and Presentations, "Top Workplace" Recognition, Q1 2026 Earnings, and Reimbursement and Enforcement Risks. Overall, the stock price has shown significant volatility, with a 93.24% increase over the past six months and a 125.3% increase since the beginning of the year.

Biodesix, Inc. has acknowledged "seasonality historically seen in the first quarter" for its products and services. Despite this, the company has reported strong demand and visibility across its Development Services pipeline. The company's Q1 2026 results showed a 29% year-over-year increase in total test volumes, with primary care contributing 15% of these tests.

Biodesix, Inc. is a diagnostic solutions company focused on improving clinical care and outcomes for patients with lung disease and other cancers, operating in the Healthcare sector, specifically in the Diagnostics & Research industry. Its core business revolves around providing diagnostic testing services and development services to biopharmaceutical and life sciences organizations. Major products include Nodify Lung® Nodule Risk Assessment, IQLung® Cancer Treatment Guidance, COVID-19 Tests, and Development Services.

Biodesix, Inc. is headquartered in Louisville, Colorado, United States, where it operates its laboratories.

In the past year, Biodesix has maintained a positive brand reputation, evidenced by its recognition as a "Top Workplace for Third Consecutive Year" in April 2026. The company actively presents and publishes clinical data for its on-market tests, which helps drive adoption from healthcare providers and payers. Analyst consensus rates Biodesix as a "Moderate Buy."

Biodesix, Inc. has 32 institutional owners and shareholders holding a total of 2,308,532 shares. Major Institutional Owners include AIGH Capital Management LLC, Standard Life Aberdeen plc, Telemark Asset Management, LLC, Vanguard Group Inc, Monashee Investment Management LLC, Perceptive Advisors Llc, Gsa Capital Partners Llp, Perkins Capital Management Inc, Geode Capital Management, Llc, Balyasny Asset Management Llc, Soleus Capital Master Fund, L.P., Soleus Capital Management, L.P., and BlackRock, Inc.